ClinicalTrialStartPulse: all 1,000 record reports, page 4 of 5

Every ClinicalTrialStartPulse record report, 200 per page, grouped by state. Records 601 to 800: University of Geneva, Switzerland: Observational study in Sepsis, Long Term Care (530 participants) to Janssen Research & Development, LLC: Phase 2 study started recruiting, 440 planned (Asthma). Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.

NONUS

• University of Geneva, Switzerland: Observational study in Sepsis, Long Term Care (530 participants)
• University of Helsinki: Not applicable (device, behavioral) study in Learning, Comprehensive Wellbeing (1440 participants)
• University of Jordan: Early phase 1 study in Benign Paroxismal Positional Vertigo (404 participants)
• University of Karachi: Not applicable (device, behavioral) study in Focus of the Study is Smoking Cessation and Prevention, Smoking Prevention (600 participants)
• University of L'Aquila: Observational study in Stroke, Malignancies Multiple (1000 participants)
• University of Latvia: Observational study in Helicobacter Pylori Infection, Colorectal Cancer (8000 participants)
• University of Malaya: Phase 2 study in Type 2 Diabetes Mellitus (DM) (360 participants)
• University of Medicine and Pharmacy at Ho Chi Minh City: Not applicable (device, behavioral) study in Depression - Major Depressive Disorder (550 participants)
• University of Minnesota: Not applicable (device, behavioral) study closed enrollment, 312 enrolled (Health Knowledge, Attitudes, Practice, Training)
• University of Minnesota: Observational study closed enrollment, 21680 enrolled (Cardiovascular Diseases, Pulmonary Embolism)
• University of Monastir: Observational study in Adherence, Medication (3000 participants)
• University of Monastir: Observational study in Lower Extremity Injuries, Venous Thromboembolism (VTE) (1500 participants)
• University of North Carolina, Chapel Hill: Not applicable (device, behavioral) study closed enrollment, 3234 enrolled (HIV-1-infection, Unhealthy Alcohol Use)
• University of North Carolina, Chapel Hill: Not applicable (device, behavioral) study in Malaria (Plasmodium Falciparum), Malaria Incidence (1350 participants)
• University of Novi Sad: Not applicable (device, behavioral) study in Postural Alignment, Posture (398 participants)
• University of Oulu: Not applicable (device, behavioral) study in Acute Low Back Pain (Low Back Pain for Less Than 3 Months) (461 participants)
• University of Oxford: Observational study in Spinal Muscular Atrophy (SMA) (750000 participants)
• University of Oxford: Phase 2 study completed, 390 enrolled (Malaria,Falciparum)
• University of Salford: Observational study completed, 1161 enrolled (Rhabdomyolysis, Death)
• University of Sao Paulo General Hospital: Phase 4 study started recruiting, 352 planned (Autoimmune Rheumatic Diseases, Tooth Extraction)
• University of Sao Paulo: Observational study in Sudden Cardiac Death, Cardiac Arrhythmias (334 participants)
• University of Southern Denmark: Observational study in Tobacco Use Behavior, Nicotine Dependence Tobacco Product (10000 participants)
• University of Texas Southwestern Medical Center: Observational study in Cancer, Malignant Neoplasm (10000 participants)
• University of Ulm: Not applicable (device, behavioral) study closed enrollment, 399 enrolled (Amyotrophic Lateral Sclerosis)
• University of Washington: Not applicable (device, behavioral) study in Breast Cancer (873 participants)
• University of Washington: Not applicable (device, behavioral) study in Hearing Loss, Bilateral or Unilateral, Otitis Media With Effusion in Children (400 participants)
• University of Wisconsin, Madison: Not applicable (device, behavioral) study closed enrollment, 449 enrolled (Hypertension)
• University of Yalova: Observational study in Education Nursing (346 participants)
• University of Zurich: Observational study in Postpartum Hemorrhage, Treatment Outcome (380 participants)
• VASCage GmbH: Observational study in Chronic Obstructive Pulmonary Disease (COPD), Severe Asthma (350 participants)
• Vejle Hospital: Observational study started recruiting, 400 planned (Subacromial Pain Syndrome, Rotator Cuff Related Shoulder Pain)
• Vestre Viken Hospital Trust: Phase 4 study in Coronary Arterial Disease (CAD) (7000 participants)
• Vietnam Military Medical University: Not applicable (device, behavioral) study started recruiting, 380 planned (Infertility (IVF Patients), Infertility Assisted Reproductive Technology)
• Viking Therapeutics, Inc.: Phase 3 study in Weight Loss (560 participants)
• Viking Therapeutics, Inc.: Phase 3 study in Weight Loss (560 participants)
• Washington University School of Medicine: Not applicable (device, behavioral) study completed, 1515 enrolled (Moderate Acute Malnutrition)
• Washington University School of Medicine: Not applicable (device, behavioral) study in HIV, HIV - Human Immunodeficiency Virus (1500 participants)
• Wellbeing Services County of Pirkanmaa: Not applicable (device, behavioral) study started recruiting, 600 planned (Hypertension)
• West China Hospital: Observational study in Liver Metastases, Gastric Adenocarcinoma (700 participants)
• West China Hospital: Observational study in Resectable Hepatocellular Carcinoma (HCC) (380 participants)
• West China Hospital: Phase 3 study in Non-small Cell Lung Cancer (NSCLC) (1088 participants)
• Wockhardt: Phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP) (324 participants)
• Women's Cancer Study Group GmbH: Phase 3 study closed enrollment, 1684 enrolled (Breast Cancer Female)
• Women's Hospital School Of Medicine Zhejiang University: Observational study in Pregnancy Complicated With Intrauterine Adhesion (360 participants)
• Wonju Severance Christian Hospital: Not applicable (device, behavioral) study in Gynecologic Surgery, General Anesthesia (350 participants)
• World Vision US: Observational study in Child Malnutrition, Wasting Syndrome (571 participants)
• Xiangya Hospital of Central South University: Not applicable (device, behavioral) study in Type 2 Diabetes Mellitus (15400 participants)
• Xuanwu Hospital, Beijing: Not applicable (device, behavioral) study in Acute Ischemic Stroke (1200 participants)
• Xuanwu Hospital, Beijing: Not applicable (device, behavioral) study in Acute Ischemic Stroke (320 participants)
• Xuanwu Hospital, Beijing: Observational study in Mild Cognitive Impairment (MCI) (600 participants)
• Yonsei University: Observational study in Coronary Artery Disease (600 participants)
• Yonsei University: Observational study in Neurodegenerative Disease, Mild Cognitive Impairmen (1550 participants)
• Yonsei University: Observational study in Patients Undergoing Valvular Heart Surgery (4230 participants)
• Yonsei University: Phase 4 study in Nonobstructive Hypertrophic Cardiomyopathy (440 participants)
• Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.: Phase 3 study in Diabetic Peripheral Neuropathic Pain (DPNP) (400 participants)
• Zhejiang Hospital: Not applicable (device, behavioral) study in Coronary Artery Disease (554 participants)
• Zhejiang Hospital: Observational study in Coronary Artery Disease (326 participants)
• Zhongnan Hospital: Observational study in PICC-associated Thrombosis (1655 participants)
• Zhongshan Ophthalmic Center, Sun Yat-sen University: Not applicable (device, behavioral) study in Refractive Errors (508 participants)
• Zhongshan Ophthalmic Center, Sun Yat-sen University: Not applicable (device, behavioral) study in Systemic Health Risk (2000 participants)

US

• 4D Molecular Therapeutics: Phase 3 study in Diabetic Macular Edema (DME) (514 participants)
• Abbott Point of Care: Observational study in Lactate (425 participants)
• AbbVie: Observational study completed, 8250 enrolled (Ulcerative Colitis (UC))
• AbbVie: Phase 3 study closed enrollment, 2701 enrolled (Hypothyroidism)
• AbbVie: Phase 3 study closed enrollment, 699 enrolled (Atopic Dermatitis)
• Abramson Cancer Center at Penn Medicine: Not applicable (device, behavioral) study in Genetic Predisposition to Cancer (1000 participants)
• Accelerated Cure Project for Multiple Sclerosis: Observational study closed enrollment, 3226 enrolled (Multiple Sclerosis, Transverse Myelitis)
• AcQumen Medical, Inc.: Observational study in Hemodynamic Monitoring (400 participants)
• Active Genomes Expressed Diagnostics, Corp: Observational study in MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) (500 participants)
• Agios Pharmaceuticals, Inc.: Observational study closed enrollment, 500 enrolled (Pyruvate Kinase Deficiency)
• AI Agent Vault, Inc. d/b/a Precision Mito: Observational study in Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome (400 participants)
• Alexion Pharmaceuticals, Inc.: Phase 3 study closed enrollment, 1182 enrolled (Transthyretin Amyloid Cardiomyopathy)
• Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute): Not applicable (device, behavioral) study in Atrial Fibrillation (AF) (334 participants)
• Alliance for Clinical Trials in Oncology: Phase 3 study closed enrollment, 1167 enrolled (Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8)
• Alpha-1 Foundation: Observational study in Alpha-1 Antitrypsin Deficiency, AATD (1000 participants)
• American College of Cardiology: Observational study in Aortic Valve Stenosis (50000 participants)
• Amgen: Phase 3 study closed enrollment, 7297 enrolled (Atherosclerotic Cardiovascular Disease)
• Andreas NLP (Legal Entity - Real People Press): Not applicable (device, behavioral) study in Psychological Distress, Psychological Well-being (480 participants)
• Annexon, Inc.: Phase 3 study closed enrollment, 659 enrolled (Geographic Atrophy)
• Apogee Therapeutics, Inc.: Phase 2 study closed enrollment, 470 enrolled (Atopic Dermatitis)
• Apple Inc.: Observational study terminated, 268037 enrolled (Hearing Loss, Noise-Induced, Hearing Loss)
• Aragon Pharmaceuticals, Inc.: Phase 3 study closed enrollment, 1503 enrolled (Prostatic Neoplasms)
• ArriVent BioPharma, Inc.: Phase 3 study closed enrollment, 398 enrolled (Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer)
• Ascendis Pharma Oncology Division A/S: Phase 2 study closed enrollment, 320 enrolled (Advanced Solid Tumor, Locally Advanced Solid Tumor)
• Astellas Pharma Global Development, Inc.: Observational study closed enrollment, 488 enrolled (Geographic Atrophy, Macular Degeneration)
• Astellas Pharma Global Development, Inc.: Phase 2 study closed enrollment, 393 enrolled (Pancreatic Cancer, Metastatic Pancreatic Cancer)
• AstraZeneca: Observational study completed, 8681 enrolled (Asthma)
• AstraZeneca: Phase 2 study closed enrollment, 477 enrolled (Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorecta
• AstraZeneca: Phase 3 study closed enrollment, 1157 enrolled (Breast Cancer, HER2-positive)
• AstraZeneca: Phase 3 study closed enrollment, 1174 enrolled (Breast Cancer)
• AstraZeneca: Phase 3 study closed enrollment, 1350 enrolled (NSCLC)
• AstraZeneca: Phase 3 study closed enrollment, 1835 enrolled (Chronic Kidney Disease With High Proteinuria)
• AstraZeneca: Phase 3 study closed enrollment, 1902 enrolled (Breast Cancer)
• AstraZeneca: Phase 3 study closed enrollment, 363 enrolled (Lupus Nephritis)
• AstraZeneca: Phase 3 study closed enrollment, 640 enrolled (Esophageal Squamous Cell Carcinoma)
• AstraZeneca: Phase 3 study closed enrollment, 760 enrolled (Biliary Tract Cancer)
• AstraZeneca: Phase 3 study closed enrollment, 768 enrolled (Metastatic Non-small Cell Lung Cancer)
• AstraZeneca: Phase 3 study closed enrollment, 863 enrolled (Unresectable Pleural Mesothelioma)
• AstraZeneca: Phase 3 study started recruiting, 1330 planned (Metastatic Hormone-Sensitive Prostate Cancer (mHSPC))
• AstraZeneca: Phase 3 study started recruiting, 600 planned (Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer)
• AstraZeneca: Phase 3 study started recruiting, 750 planned (Newly Diagnosed Multiple Myeloma (NDMM))
• Avalyn Pharma Inc.: Phase 2 study closed enrollment, 398 enrolled (Pulmonary Fibrosis, Progressive Pulmonary Fibrosis)
• Azienda Unità Sanitaria Locale della Romagna: Observational study completed, 4230 enrolled (Acute Ischemic Stroke Related to Tandem Occlusion, Acute Ischemic Stroke Due to Isolated Cervical Artery Occlusion)
• Bactolife A/S: Not applicable (device, behavioral) study in Gut Health, Gastrointestinal Symptoms (800 participants)
• Baptist Health South Florida: Not applicable (device, behavioral) study completed, 335 enrolled (Perceptions of Caring, Hospital Readmissions)
• Bayer: Observational study closed enrollment, 4613 enrolled (Chronic Kidney Disease, Type 2 Diabetes Mellitus)
• Baylor Research Institute: Observational study in Surgical Site Infection, Vaginal Cuff Cellulitis (900 participants)
• Beeline Medicines Corporation: Phase 3 study in Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus (390 participants)
• BeiGene: Phase 2 study completed, 418 enrolled (Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer)
• BeOne Medicines: Phase 3 study closed enrollment, 799 enrolled (Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma)
• BioNTech SE: Phase 1 study closed enrollment, 318 enrolled (Genital Herpes Simplex Type 2)
• BioNTech SE: Phase 3 study closed enrollment, 358 enrolled (Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer)
• BioNTech SE: Phase 3 study completed, 5240 enrolled (COVID-19, SARS-COV-2 Infection)
• Bladder Cancer Advocacy Network: Observational study in NMIBC, MIBC (1400 participants)
• Boston Medical Center: Not applicable (device, behavioral) study closed enrollment, 600 enrolled (Parent-Child Relations, Parenting)
• Boston Scientific Corporation: Not applicable (device, behavioral) study closed enrollment, 3000 enrolled (Atrial Fibrillation, Stroke)
• Boston Scientific Corporation: Not applicable (device, behavioral) study closed enrollment, 500 enrolled (Prostate Cancer)
• Boston Scientific Corporation: Not applicable (device, behavioral) study started recruiting, 400 planned (Atrial Fibrillation (AF), Stroke)
• Brigham and Women's Hospital: Not applicable (device, behavioral) study closed enrollment, 640 enrolled (Genetic Predisposition to Disease, Hereditary Diseases)
• Brigham and Women's Hospital: Observational study closed enrollment, 10718 enrolled (Pulmonary Disease, Chronic Obstructive, Emphysema)
• Brigham and Women's Hospital: Observational study in Metastatic Colorectal Cancer (mCRC) (1030 participants)
• Brigham and Women's Hospital: Observational study in Metastatic Colorectal Cancer (mCRC) (400 participants)
• Brigham and Women's Hospital: Observational study in Metastatic Colorectal Cancer (mCRC) (9978 participants)
• Bristol-Myers Squibb: Phase 3 study completed, 1314 enrolled (Urothelial Cancer)
• Brown University: Not applicable (device, behavioral) study closed enrollment, 2300 enrolled (Healthy)
• Calyxo, Inc.: Observational study started recruiting, 1000 planned (Urolithiasis, Stones, Kidney)
• Cardiology Consultants of Philadelphia: Observational study in ASCVD (2500 participants)
• Carmot Therapeutics, Inc.: Phase 2 study completed, 447 enrolled (Overweight or Obese, Type 2 Diabetes Mellitus (T2DM))
• Chestnut Health Systems: Phase 3 study in Substance Use Disorder (SUD), Opioid Use Disorders (600 participants)
• Children's Hospital Medical Center, Cincinnati: Not applicable (device, behavioral) study closed enrollment, 787 enrolled (Genetic Screening, Adolescent)
• Children's Hospital Medical Center, Cincinnati: Observational study completed, 1102 enrolled (Depression Disorders, Suicidality)
• Children's Hospital of Philadelphia: Not applicable (device, behavioral) study in Postpartum Complication, Postpartum (640 participants)
• Children's Hospital of Philadelphia: Not applicable (device, behavioral) study in Postpartum, Postpartum Depression (PPD) (756 participants)
• Children's Hospital of Philadelphia: Observational study in Cardiac Arrest (CA) (1620 participants)
• Children's Oncology Group: Phase 3 study closed enrollment, 391 enrolled (Ganglioneuroblastoma, Localized Resectable Neuroblastoma)
• City of Hope Medical Center: Not applicable (device, behavioral) study closed enrollment, 1062 enrolled (Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment)
• City of Hope Medical Center: Not applicable (device, behavioral) study closed enrollment, 344 enrolled (Healthy Subject)
• City of Hope Medical Center: Observational study started recruiting, 423 planned (Breast Carcinoma)
• Columbia University: Not applicable (device, behavioral) study closed enrollment, 23928 enrolled (Hypertension)
• Columbia University: Not applicable (device, behavioral) study closed enrollment, 749 enrolled (Glaucoma, Vision Impairment and Blindness)
• Columbia University: Phase 3 study started recruiting, 1010 planned (Abdominal Pain, Isolated Extremity Fracture)
• Connecticut Children's Medical Center: Phase 4 study closed enrollment, 1270 enrolled (Crohn Disease)
• CorDx, Inc.: Not applicable (device, behavioral) study in SARS-CoV-2 Infection, Influenza A (1500 participants)
• Dana-Farber Cancer Institute: Phase 2 study closed enrollment, 393 enrolled (HER2-positive Breast Cancer, Invasive Carcinoma of the Breast)
• Day One Biopharmaceuticals, Inc.: Phase 3 study closed enrollment, 418 enrolled (Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma)
• Deepull Diagnostics S.L.: Observational study in Blood Stream Infection, Blood Stream Infections (1500 participants)
• DePuy International: Not applicable (device, behavioral) study closed enrollment, 1542 enrolled (Noninflammatory Degenerative Joint Disease)
• DePuy Orthopaedics: Not applicable (device, behavioral) study closed enrollment, 400 enrolled (Primary Knee Arthroplasty)
• DePuy Orthopaedics: Not applicable (device, behavioral) study closed enrollment, 400 enrolled (Revision Total Knee Arthroplasty)
• dfusion Inc: Not applicable (device, behavioral) study in Education, Sex (365 participants)
• dōTERRA International: Not applicable (device, behavioral) study completed, 313 enrolled (Healthy)
• Duke University: Not applicable (device, behavioral) study completed, 1800 enrolled (Pain, Back)
• Eastern Cooperative Oncology Group: Phase 3 study closed enrollment, 540 enrolled (Brain and Central Nervous System Tumors, Neurotoxicity)
• ECOG-ACRIN Cancer Research Group: Phase 2 study closed enrollment, 2175 enrolled (Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8)
• ECOG-ACRIN Cancer Research Group: Phase 3 study closed enrollment, 1087 enrolled (Plasma Cell Myeloma)
• Eisai Inc.: Phase 3 study closed enrollment, 1906 enrolled (Early Alzheimer's Disease)
• Eli Lilly and Company: Phase 1 study in Obesity, Overweight (617 participants)
• Eli Lilly and Company: Phase 2 study in Obesity, Overweight (460 participants)
• Eli Lilly and Company: Phase 3 study closed enrollment, 15374 enrolled (Obesity, Overweight)
• Eli Lilly and Company: Phase 3 study in Obesity (2115 participants)
• Eli Lilly and Company: Phase 3 study in Obesity, Overweight (1000 participants)
• Eli Lilly and Company: Phase 3 study in Obesity, Overweight (3000 participants)
• Emory University: Not applicable (device, behavioral) study closed enrollment, 473 enrolled (HIV Infections, STI)
• Enanta Pharmaceuticals, Inc: Phase 3 study in RSV (860 participants)
• Encora, Inc.: Observational study in Essential Tremor (1000 participants)
• Epizyme, Inc.: Phase 3 study closed enrollment, 599 enrolled (Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma)
• Ethicon Endo-Surgery: Observational study closed enrollment, 500 enrolled (Gastroesophageal Reflux)
• Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Observational study closed enrollment, 52966 enrolled (Suicide Mortality)
• EyeBiotech Ltd.: Phase 3 study closed enrollment, 1054 enrolled (Diabetic Macular Edema (DME))
• Florida State University: Not applicable (device, behavioral) study in Alcohol Drinking, HIV Infections (360 participants)
• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico: Observational study in Chronic Lung Diseases (683 participants)
• Fred Hutchinson Cancer Center: Not applicable (device, behavioral) study closed enrollment, 374 enrolled (Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm)
• Geisinger Clinic: Not applicable (device, behavioral) study completed, 51218 enrolled (Influenza, Vaccination)
• Genentech, Inc.: Phase 4 study completed, 403 enrolled (Spinal Muscular Atrophy)
• Genmab: Phase 2 study closed enrollment, 543 enrolled (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma)
• Genmab: Phase 2 study closed enrollment, 666 enrolled (DLBCL, High-grade B-cell Lymphoma (HGBCL))
• Genmab: Phase 3 study closed enrollment, 621 enrolled (Head and Neck Squamous Cell Carcinoma)
• Genmab: Phase 3 study closed enrollment, 699 enrolled (Head and Neck Squamous Cell Carcinoma)
• Genmab: Phase 3 study started recruiting, 600 planned (Colorectal Cancer)
• George Washington University: Not applicable (device, behavioral) study started recruiting, 588 planned (Colorectal Cancer)
• George Washington University: Observational study in Influenza, COVID-19 (550 participants)
• H. Lundbeck A/S: Phase 3 study closed enrollment, 401 enrolled (Multiple System Atrophy)
• Harvard School of Public Health (HSPH): Not applicable (device, behavioral) study in Dietary Intakes, Physical Activity (456 participants)
• Health Sciences North Research Institute: Phase 4 study completed, 393 enrolled (Elderly Immune System)
• HeartFlow, Inc.: Not applicable (device, behavioral) study in CAD - Coronary Artery Disease (500 participants)
• Hoffmann-La Roche: Phase 3 study closed enrollment, 382 enrolled (Cancer)
• Hoffmann-La Roche: Phase 3 study closed enrollment, 459 enrolled (Primary IgA Nephropathy)
• Hoffmann-La Roche: Phase 3 study closed enrollment, 672 enrolled (Diabetic Macular Edema)
• Hoffmann-La Roche: Phase 3 study started recruiting, 400 planned (Non-small Cell Lung Cancer)
• Inari Medical: Not applicable (device, behavioral) study completed, 1200 enrolled (Pulmonary Embolism)
• Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz: Observational study in Tumor Burden, Neuroendocrine (NE) Tumors (400 participants)
• Intra-Cellular Therapies, Inc.: Phase 3 study in Generalized Anxiety Disorder (705 participants)
• Jade Biosciences, Inc.: Phase 3 study in IgA Nephropathy (IgAN) (480 participants)
• Janssen Biotech, Inc.: Observational study closed enrollment, 4970 enrolled (Crohn's Disease, Ulcerative Colitis)
• Janssen Biotech, Inc.: Observational study closed enrollment, 535 enrolled (Ulcerative Colitis)
• Janssen Pharmaceutica N.V., Belgium: Phase 3 study closed enrollment, 691 enrolled (Prostatic Neoplasms)
• Janssen Research & Development, LLC: Phase 1 study closed enrollment, 701 enrolled (Carcinoma, Non-Small-Cell Lung)
• Janssen Research & Development, LLC: Phase 1 study closed enrollment, 751 enrolled (Non-Small-Cell Lung Cancer)
• Janssen Research & Development, LLC: Phase 2 study closed enrollment, 333 enrolled (Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma)
• Janssen Research & Development, LLC: Phase 2 study started recruiting, 440 planned (Asthma)

Browse ClinicalTrialStartPulse by category and location · Search and filter ClinicalTrialStartPulse